Robin Carlstein, senior vice president of advanced wound devices at Smith & Nephew, said: “Smith & Nephew welcomes the appeals court decision that our Versatile 1 negative pressure wound therapy system does not infringe KCI’s patents.
“Today’s decision affirmed our long-held belief that our gauze-based systems are a legitimate offering in the broader negative pressure wound therapy market. Smith & Nephew will continue operating in this important space. Most importantly, we remain dedicated to using innovative technologies to improve patients’ lives.”